Chronic Obstructive Pulmonary Diseases:Journal of the COPD Foundation

Articles in Press

Peer-reviewed, accepted articles are posted in Articles in Press shortly after editorial acceptance. These posted articles (below) have completed a rigorous peer review process but the articles have NOT been copyedited or designed. Copyedited, designed, final versions of these articles will be created and published in a Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) upcoming issue. Articles in Press citations/abstracts are submitted to PubMed.

To receive notifications of the posting of new Articles in Press AND the posting of new JCOPDF issues, sign up for a FREE SUBSCRIPTION HERE.

Psychobiologic Correlates of Stress in Individuals With COPD

Trisha M. Parekh, DO, MSPH1 Rekha Ramachandran, MS2 Young-il Kim, PhD2 Zahra Haider3 Darlene Bhavnani, PhD, MPH4 J. Michael Wells, MD, MSPH5,6,7 Elizabeth Matsui, MD4 Mark T. Dransfield, MD5,6,7

Citation: Parekh TM, Ramachandran R, Kim Y, et al. Psychobiologic correlates of stress in individuals with COPD. Chronic Obstr Pulm Dis. 2025; Published online May 8, 2025. doi: https://doi.org/10.15326/jcopdf.2024.0578

View Pre-proof PDF

The Role of MicroRNA-144 in Regulating Airway Immune Dysfunction in COPD Through the Transforming Growth Factor-Beta/Polymeric Immunoglobulin Receptor Pathway: An In Vitro Study

Hu Liu1 Yun Zhao1 Jing Cao1 Lei Liang1 Jinmeng Zhou2

Citation: Liu H, Zhao Y, Cao J, Liang L, Zhou J. The role of microRNA-144 in regulating airway immune dysfunction in COPD through the transforming growth factor-beta/polymeric immunoglobulin receptor pathway: an in vitro study. Chronic Obstr Pulm Dis. 2025; Published online April 25, 2025. doi: https://doi.org/10.15326/jcopdf.2024.0592

View Pre-proof PDF

Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial

Katherine Hickman1,2,3 Yasir Tarabichi4 Andrew P. Dickens5 Rachel Pullen5 Margee Kerr5,6 Amy Couper5,6 Alexander Evans6 James Gatenby6 Luis Alves7,8 Cono Ariti5 Mona Bafadhel9 Victoria Carter6 James Chalmers10 Rongchang Chen11 Graham Devereux12 M. Bradley Drummond13 J. Martin Gibson14,15,16 David M. G. Halpin17 MeiLan Han18 Nicola A Hanania19 John R. Hurst20 Alan Kaplan5,21,22 Konstantinos Kostikas5,23 Barry Make24 Douglas Mapel25 Jonathan Marshall26 Fernando Martinez27 Catherine Meldrum28 Marije van Melle5,29 Marc Miravitlles30 Tamsin Morris31 Hana Mullerova32 Ruth Murray6 Shigeo Muro33 Clementine Nordon32 Jill Ohar34 Wilson Pace35,36 Michael Pollack37 Jennifer K. Quint38 Anita Sharma39 Dave Singh40 Mukesh Singh41,42,43 Frank Trudo37 Dennis Williams44,45 Tom Wilkinson46,47,48 Tonya Winders49 David Price5,6,50

Citation: Hickman K, Tarabichi Y, Dickens AP, et al. Pragmatic evaluation of an improvement program for people living with modifiable high-risk COPD versus usual care: protocol for the cluster randomized PREVAIL trial. Chronic Obstr Pulm Dis. 2025; Published online April 25, 2025. doi: https://doi.org/10.15326/jcopdf.2024.0564

View Pre-proof PDF

Rationale and Design of the Alpha-1 Biomarkers Consortium Study

Monica P. Goldklang1 Cheryl Pirozzi2 Igor Barjaktarevic3 Surya Bhatt4 Sandeep Bodduluri4 M. Bradley Drummond5 D. Kyle Hogarth6 Alison Keaveny7 Zhonghua Liu1 Noel G. McElvaney8 Oliver J. McElvaney8 Nadine Nuchovich7 Sabrina Palumbo1 Randel Plant7 Robert Sandhaus9 J. Michael Wells4 Andrew Wilson10 Charlie Strange11 Jeanine M. D’Armiento1 for the Alpha-1 Biomarker Consortium Study Group

Citation: Goldklang MP, Pirozzi C, Barjaktarevic I, et al. Rationale and design of the alpha-1 biomarkers consortium study. Chronic Obstr Pulm Dis. 2025; Published online April 24, 2025. doi: https://doi.org/10.15326/jcopdf.2025.0603

View Pre-proof PDF

Inhalation Innovation: Optimizing COPD Care Through Clinical Pharmacist Integration in a Rehabilitation Hospital's Multidisciplinary Team – A Quality Improvement Study

Annelies Walravens1* Emma Walravens1,2* Stephanie Wuyts2,3 Sander Boudewyn4 Kayleigh Spriet4 Kristel De Paepe4 Eline Tommelein5

Citation: Walravens A, Walravens E, Wuyts S, et al. Inhalation innovation: optimizing COPD care through clinical pharmacist integration in a rehabilitation hospital's multidisciplinary team – a quality improvement study. Chronic Obstr Pulm Dis. 2025; Published online April 1, 2025. doi: https://doi.org/10.15326/jcopdf.2024.0569

View Pre-proof PDF

Erratum:

Erratum

Wang Chun Kwok, MBBS1 Terence Chi Chun Tam, MBBS1 Chi Hung Chau, MBBS2 Fai Man Lam, MBBS2 James Chung Man Ho, MD1

Author Affiliations

  1. Division of Respiratory Medicine, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  2. Tuberculosis and Chest Unit, Grantham Hospital, Aberdeen, Hong Kong Special Administrative Region, China

Address correspondence to:

There is no correspondance information for this article.

Abstract

Background: Pseudomonas aeruginosa is an important pathogen in patients with chronic respiratory diseases. It can colonize the airways and could have prognostic value in bronchiectasis and cystic fibrosis. Its role in chronic obstructive pulmonary disease (COPD) is less well-defined.

Methods: A prospective study was conducted in Hong Kong to investigate the possible association between Pseudomonas aeruginosa colonization and acute exacerbation of COPD (AECOPD) risks.

Results: Among 327 Chinese patients with COPD, 33 (10.1%) of the patients had Pseudomonas aeruginosa colonization. Patients with or without Pseudomonas aeruginosa colonization had similar background characteristics. Patients with Pseudomonas aeruginosa colonization had increased risks of moderate to severe AECOPD, severe AECOPD, and pneumonia with an adjusted odds ratio (aOR) of 3.15 (95% CI 1.05−9.48, p=0.042), 2.59 (95% CI 1.01₋6.64, p=0.048), and 4.19 (95% CI 1.40₋12.54, p=0.011) respectively. Patients with Pseudomonas aeruginosa colonization also had increased annual frequency of moderate to severe AECOPDs, median 0 (0₋0.93) in the non-Pseudomonas aeruginosa colonization group and 1.35 (0₋3.39) in the Pseudomonas aeruginosa colonization group, with a p-value of 0.005 in multivariate linear regression.

Conclusion: Pseudomonas aeruginosa colonization is a potential independent risk factor for moderate to severe AECOPD and pneumonia among patients with COPD without coexisting bronchiectasis.

Citation

Citation: Erratum. Chronic Obstr Pulm Dis. 2025; 12(3): 212-212. doi: http://dx.doi.org/10.15326/jcopdf.2024.0582E

Keywords

There are no keywords for this article.

PDF Download

PDF PDF Version (56KB)
Copyright 2025 by COPD Foundation Disclaimer| Privacy|

The COPD Foundation is a nonprofit, tax-exempt charitable organization under Section 501(c)(3) of the Internal Revenue Code.